NCT03527355 - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine | Biotech Hunter

Enrollment

285

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

July 28, 2018

Study Completion Date

January 19, 2021

Conditions

Typhoid

Interventions

BIOLOGICAL

Vi-DT

Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial

BIOLOGICAL

FluQuadri™

"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."

OTHER

0.9% sodium chloride isotonic solution

Manufacture: Euro-Med Inc. Dose: 0.5 mL

Trial Locations (1)

1781

Research Institute for Tropical Medicine(RITM), Alabang

All Listed Sponsors

collaborator

SK Bioscience Co., Ltd.

INDUSTRY

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

International Vaccine Institute

OTHER